- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
re: AUPH - Aurinia Pharmaceuticals
Posted on 11/3/23 at 9:23 am to Rendevoustavern
Posted on 11/3/23 at 9:23 am to Rendevoustavern
Why I'm still here:
The drug is simply too effective for an unmet need not to get scooped up.
LINK
quote:
In a subset analysis of three years of data from the AURORA Clinical Program, 44.4% of Black patients treated with LUPKYNIS? experienced an improvement in complete renal response at 36 months (n=18) compared to 14.3% of Black patients who achieved complete renal response when treated with MMF and glucocorticoids alone (n= 7).
The drug is simply too effective for an unmet need not to get scooped up.
LINK
2
Posted on 11/3/23 at 2:06 pm to bayoubengals88
Looked much into BMRN?
Posted on 11/3/23 at 5:47 pm to LSUcam7
quote:Nah, honestly I haven’t looked into much of anything (including AUPH).
Looked much into BMRN?
Got a growing family and a new lawn obsession
Posted on 11/10/23 at 1:25 pm to bayoubengals88
Bayou
Exactly, which is why I did not understand this dip. It had been rainbows and lollipops. From outsiders and stock sites. And still they are on board with the stick and it sits there lifeless.
I think with trials and the ability to continue selling in Europe and newer countries down the road, that we should be in 13-14 range and offers in 25-33. Range, at worst
I read this thread 3 times and did homework before I bought in. I thought the drug had major upside and company could be a sure sale at a nice price. This drug is like being a Missouri tiger fan, when anything good begins to happen, bam,kick to the nuts, back to reality same sorry arse tigers
Exactly, which is why I did not understand this dip. It had been rainbows and lollipops. From outsiders and stock sites. And still they are on board with the stick and it sits there lifeless.
I think with trials and the ability to continue selling in Europe and newer countries down the road, that we should be in 13-14 range and offers in 25-33. Range, at worst
I read this thread 3 times and did homework before I bought in. I thought the drug had major upside and company could be a sure sale at a nice price. This drug is like being a Missouri tiger fan, when anything good begins to happen, bam,kick to the nuts, back to reality same sorry arse tigers
Posted on 11/10/23 at 2:24 pm to SeeeeK
quote:Perhaps the most promising aspect is the 3.7 million in royalty payments from Otsuka for Q3 alone.
I think with trials and the ability to continue selling in Europe and newer countries down the road, that we should be in 13-14 range and offers in 25-33. Range, at worst
If the royalty percentage is 15% of product sold then Otsuka sold 25 million of European product during Q3 alone. And they just got started there...
As a bigger and more capable company they are able to sell the drug for far cheaper in Europe, which makes it much more attractive (obviously).
Any buyer would love to see this and implement the cheaper price in the states. It could be Otsuka if they can afford it.
quote:
December 17, 2020 • 4:00 am EST
- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
As part of the agreement, Aurinia will receive an upfront cash payment of $50 million U.S. and has the potential to receive up to $50 million U.S. in regulatory and reimbursement milestone payments. Aurinia will receive tiered royalties ranging from 10 to 20 percent (dependent on achievement of sale milestones) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka.
--------------
That being said, I still don't know why we're spending over 60 million/quarter.
But still 338 million cash on hand
Posted on 11/10/23 at 2:30 pm to bayoubengals88
When u have that much cash the big co.panies smell blood in water and come to buy.
Chrysler had 900mil in cash, and Mercedes came in like a vulture and bought them, and used cash to buy 5 other companies
Chrysler had 900mil in cash, and Mercedes came in like a vulture and bought them, and used cash to buy 5 other companies
Posted on 11/10/23 at 2:55 pm to SeeeeK
Out today:
Posted on 11/10/23 at 3:33 pm to bayoubengals88
Otsuka is going to buy this company 
Posted on 11/10/23 at 7:01 pm to Turftoe
They need to do that shite before January…
Posted on 11/14/23 at 8:33 am to jimjackandjose
Posted on 11/20/23 at 7:55 pm to Sgt_Lincoln_Osiris
Been on a good little run the last couple of days.
Posted on 11/21/23 at 9:20 am to lilyankems
I haven’t been intrigued until this morning though.
Hit daily volume in just 30 minutes.
Hit daily volume in just 30 minutes.
Posted on 11/21/23 at 9:20 am to bayoubengals88
A wise investor would sell his January calls now
Posted on 11/21/23 at 9:26 am to bayoubengals88
Toying with covered calls this morning
Posted on 11/21/23 at 11:52 am to ynlvr
Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors
Investing.com | Editor Nikhilesh Pawar
Published Nov 21, 2023 12:39PM ET
Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors
Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ:AUPH) saw a notable increase today, rising by 6.7% amid speculation about a potential acquisition by Gilead Sciences (NASDAQ:GILD). The rumors were sparked by the sighting of a Gilead jet at the Edmonton headquarters of Aurinia, suggesting that discussions might be underway. This comes after Aurinia's announcement in June about exploring strategic alternatives.
Investing.com | Editor Nikhilesh Pawar
Published Nov 21, 2023 12:39PM ET
Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors
Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ:AUPH) saw a notable increase today, rising by 6.7% amid speculation about a potential acquisition by Gilead Sciences (NASDAQ:GILD). The rumors were sparked by the sighting of a Gilead jet at the Edmonton headquarters of Aurinia, suggesting that discussions might be underway. This comes after Aurinia's announcement in June about exploring strategic alternatives.
Posted on 11/21/23 at 12:34 pm to Mizzou
Posted on 11/21/23 at 1:12 pm to Fat Batman
Posted on 11/21/23 at 8:15 pm to castorinho
That was the biggest pump and dump scheme Eva today
Posted on 11/22/23 at 12:00 am to jimjackandjose
quote:
That was the biggest pump and dump scheme Eva today
What's worse is they're getting less and less sophisticated.. first buyout rumors had the grinning guy on CNBC, then articles in the Walt Street Journal... now we're just posting flightaware maps
Posted on 11/22/23 at 4:57 pm to jmcwhrter
Strong rebound today. Makes me think they are letting the big money shorts off the hooks.
Big volume last few days and overall great trend. This could pop off soon
Big volume last few days and overall great trend. This could pop off soon
Page 161 of 164
Popular
Back to top
Follow TigerDroppings for LSU Football News